Pfizer Canada Confirms that Sufficient EpiPen® Auto-Injector Stock Is Now Available to Meet Needs of Canadian Patients
KIRKLAND, QC, November 27, 2015 – Pfizer Canada Inc. and Health Canada are committed to the health and safety of Canadian patients. Pfizer Canada Inc. has secured sufficient quantities of EpiPen® auto-injectors to replace all remaining Allerject® (epinephrine injection, USP) devices affected by Sanofi Canada’s recent nationwide recall.
Now that full EpiPen® and EpiPen® Jr stock is available in Canada, consumers should proceed to contact their pharmacies to replace all remaining unexpired Allerject® devices in their possession. More information on the recall can be found here: http://www.allerject.ca.
EpiPen® and EpiPen® Jr (0.3 and 0.15 mg epinephrine) Auto-Injectors (“EpiPen”) are indicated for the emergency treatment of anaphylactic reactions in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. The EpiPen® Auto-Injector is a disposable, pre-filled automatic injection device that administers epinephrine in the event of a severe allergic reaction. After using EpiPen®, you must seek immediate medical attention or go to the emergency room. For the next 48 hours, you must stay close to a healthcare facility or be able to call 911. For more information about EpiPen®, please visit http://www.epipen.ca or you can follow us on Facebook (facebook.com/EpiPenCanada).
EpiPen®, EpiPen® Jr are registered trademarks of Mylan, Inc. licensed exclusively to its wholly-owned affiliate, Mylan Specialty, L.P.; sub-licensee, Pfizer Canada Inc., Kirkland, Quebec H9J 2M5
Allerject® is a trademark of Sanofi.
Pfizer Canada Inc.
Toll-free: 1 866 9PFIZER (973-4937)